SORT BY

FILTER BY

also on other fortune lists

company facts

f500 stats

Fortune 500

Chris Ratcliffe — Bloomberg via Getty Images

54

Pfizer

PFE

Pfizer landed one of 2016’s most sought-after biopharma deals with its $14 billion acquisition of cancer drug maker Medivation, beating out the likes of Sanofi. In another critical business decision, the firm announced last fall that it wouldn’t split into two publicly traded companies in order to separate its generic and branded pharmaceutical businesses, raising the prospect of even more future deals. Pfizer also came under fire over drug price increases including a record $107 million fine by U.K. regulators for hiking an epilepsy treatment’s price by 2,600%.

Looking for leads, investment insights, or competitive intelligence?

CEO

Ian C. Read

CEO Title

Chairman & Chief Executive Officer

Sector

Health Care

Industry

Pharmaceuticals

HQ Location

New York, NY

Years on Fortune 500 List

23

Employees

96,500

Profile provided by S&P Global.
Key Financials (Last Fiscal Year)
$ millions% change
Revenues ($M)$52,8248.1%
Profits ($M)$7,215.03.7%
Assets ($M)$171,615
Total Stockholder Equity ($M)$59,544
Market Value — as of March 31, 2017 ($M)$203,725
Profit Ratios
Profit as % of Revenues13.7%
Profits as % of Assets4.2%
Profits as % of Stockholder Equity12.1%
Earnings Per Share (Last Fiscal Year)
Earnings Per Share ($)1.17
EPS % Change (from 2015)5.4%
EPS % Change (5 year annual rate)-1.6%
EPS % Change (10 year annual rate)-7.9%
Total Return
Total Return to Investors (2016)4.4%
Total Return to Investors (5 year, annualized)12.3%
Total Return to Investors (10 year, annualized)6.8%
STOCK QUOTE
()0.00 0.00 (0)
  • Previous Close:
  • Market Cap: NaNB
  • Next Earnings Date:
  • High:
  • Low:
  • 52 Week High:
  • 52 Week Low:
  • 52 Week Change %: 0.00
  • P/E Ratio: n/a
  • EPS:
  • Dividend Yield: n/a

News about Pfizer

Viagra Just Turned 20. Here's How Much Money the ED Drug Makes

The "little blue pill" has been a cash cow for drug giant Pfizer.

Read More →
GlaxoSmithKline Is Buying Out Novartis's Share in Their Consumer Health Joint Venture

GSK's move comes days after it dropped its bid for Pfizer's consumer healthcare business

Read More →
Fortune Future, Trade War, GSK: CEO Daily for March 23, 2018

Must-read business news, delivered every morning.

Read More →